Vestal Point Capital LP Has $18.11 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Vestal Point Capital LP has reduced its stake in Ultragenyx Pharmaceutical Inc. by 66.7%, selling 1 million shares to hold 500,000 shares, representing about 1.3% of their portfolio.
• Ultragenyx has drawn mixed analyst ratings, with a consensus 'Moderate Buy' and an average price target of $81.50, despite varying target price changes from several investment firms.
• The company's recent earnings report showed a loss of ($1.17) per share, surpassing expectations, along with revenue growth of 13.2% year-over-year, totaling $166.5 million.

Vestal Point Capital LP cut its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 66.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 500,000 shares of the biopharmaceutical company's stock after selling 1,000,000 shares during the quarter. Ultragenyx Pharmaceutical accounts for 1.3% of Vestal Point Capital LP's portfolio, making the stock its 25th largest position. Vestal Point Capital LP owned about 0.53% of Ultragenyx Pharmaceutical worth $18,105,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. California State Teachers Retirement System increased its position in shares of Ultragenyx Pharmaceutical by 0.3% during the 4th quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company's stock valued at $3,284,000 after purchasing an additional 268 shares during the period. GAMMA Investing LLC increased its position in shares of Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 323 shares during the period. Xponance Inc. increased its position in shares of Ultragenyx Pharmaceutical by 2.8% during the 1st quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock valued at $455,000 after purchasing an additional 347 shares during the period. BOKF NA increased its position in shares of Ultragenyx Pharmaceutical by 5.0% during the 4th quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock valued at $336,000 after purchasing an additional 382 shares during the period. Finally, Oak Ridge Investments LLC increased its position in shares of Ultragenyx Pharmaceutical by 2.3% during the 1st quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company's stock valued at $643,000 after purchasing an additional 395 shares during the period. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Wedbush lowered their price target on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a research report on Monday, July 14th. Morgan Stanley decreased their target price on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a report on Monday, July 14th. William Blair initiated coverage on Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 target price on the stock. HC Wainwright upgraded Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 target price on the stock in a report on Monday, July 28th. Finally, Guggenheim restated a "buy" rating and issued a $64.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, June 20th. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $81.50.

Insider Activity at Ultragenyx Pharmaceutical

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the sale, the director owned 15,344 shares of the company's stock, valued at $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 5.50% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Stock Up 1.7%

Shares of Ultragenyx Pharmaceutical stock traded up $0.54 during midday trading on Friday, hitting $31.82. The company's stock had a trading volume of 1,325,362 shares, compared to its average volume of 1,310,061. The firm has a market capitalization of $3.07 billion, a P/E ratio of -5.75 and a beta of 0.21. The stock has a 50-day simple moving average of $30.40 and a 200-day simple moving average of $34.86. Ultragenyx Pharmaceutical Inc. has a 1-year low of $25.81 and a 1-year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. The business had revenue of $166.50 million during the quarter, compared to analysts' expectations of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.Ultragenyx Pharmaceutical's revenue was up 13.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.